Molluscum contagiosum (MC) is an infectious disease caused by the MC virus. In human immunodeficiency virus (HIV) patients, MC has an atypical predilection and prominence, sometimes measuring more than 1 cm in diameter, known as giant MC. Giant MC lesions on the eyelids are rare. There is no standardized therapy for eyelids MC in HIV patients. Antiretroviral (ARV) administration is recommended as the primary treatment for MC in HIV patients along with other treatment modalities, such as potassium hydroxide (KOH). The 20% KOH solution is a keratolytic agent with good efficacy as MC therapy. Two cases of giant MC on the eyelids of stage 2 HIV patients with respective CD4+ of 31 cells/μL and 46 cells/μL were reported. The lesions consisted of multiple confluent papules with central umbilication, and Tzanck smear revealed Henderson-Patterson bodies. Both patients were treated with ARV and self-applied 20% KOH solution once daily. The lesions improved after four weeks of therapy in both patients with most of the lesions diminished. The successful treatment with 20% KOH solution for giant MC on the eyelids of HIV patients observed in the current study provides evidence that treatment with this solution yielded prompt results, is non-toxic, and can be self-applied.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8612666 | PMC |
http://dx.doi.org/10.2147/HIV.S341856 | DOI Listing |
AIDS Patient Care STDS
January 2025
Department of Obstetrics, Gynecology & Reproductive Sciences, University of California San Francisco, Oakland, California, USA.
Community health workers (CHWs) play a significant role in supporting health services delivery in communities with few trained health care providers. There has been limited research on ways to optimize the role of CHWs in HIV prevention service delivery. This study explored CHWs' experiences with offering HIV prevention services [HIV testing and HIV pre- and post-exposure prophylaxis (PrEP and PEP)] during three pilot studies in rural communities in Kenya and Uganda, which aimed to increase biomedical HIV prevention coverage via a structured patient-centered HIV prevention delivery model.
View Article and Find Full Text PDFStem Cell Rev Rep
January 2025
Institute for Cellular and Molecular Medicine, Department of Immunology, SAMRC Extramural Unit for Stem Cell Research and Therapy, University of Pretoria, Pretoria, 0084, South Africa.
HIV Med
January 2025
National Centre for Epidemiology, Carlos III Health Institute, Madrid, Spain.
Objectives: We aimed to describe health-related quality of life (HRQoL), overall and across its dimensions, identify associated factors, and assess changes over time among people with HIV (PWH) from the Spanish multicentre CoRIS cohort.
Methods: We developed a mobile app to collect HRQoL data every 3 months using the WHOQOL-HIV-BREF questionnaire (31 items across six domains), among PWH followed in CoRIS in 2021-2023. Factors associated with good/very good global HRQoL and with domain-specific mean scores were identified using multivariable logistic and linear regression, respectively.
J Antimicrob Chemother
January 2025
Department of Laboratory Medicine, Yunnan Provincial Infectious Disease Hospital, Kunming 650301, China.
Objectives: This study aimed to evaluate the prevalence and characteristics of drug resistance mutations (DRMs) in patients with low-level viremia (LLV) in Southwestern China, as it has become a growing challenge in AIDS clinical practice.
Methods: This cross-sectional study was performed in Yunnan Province, Southwestern China. LLV was defined as 50-999 copies/mL of plasma viral load with antiretroviral therapy (ART) for at least 6 months.
Infect Drug Resist
January 2025
Department of Clinical Medicine, School of Medicine, Qinghai University, Xining, People's Republic of China.
Pneumocystis jirovecii pneumonia (PJP) is an opportunistic fungal infection that often occurs secondary to human immunodeficiency virus (HIV) infection. However, for non-HIV immunocompromised patients, such as those undergoing novel immunosuppressive treatments to manage malignancies, organ transplants, or connective tissue diseases, PJP is emerging as an increasing threat. The clinical manifestations of PJP in HIV-infected and non-HIV-infected patients differ significantly.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!